Abstract Library

#4609 External validation of Rachel score: A prognostic tool for lung neuroendocrine tumours

Introduction: Lung NETs are a heterogeneous group of tumours with variegated clinical presentation and course. The histological subtype (TC vs AC) and TNM stage are established prognostic factors. In a previous work by our group, we developed a prognostic model named Rachel score, with a satisfactory ability to predict OS and PFS in this population.

Conference:

Presenting Author: La Salvia A

Authors: La Salvia A, Marcozzi B, Lamberti G, Manai C, Mazzilli R,

Keywords: lung neuroendocrine tumour, prognostic tool, Rachel score, external cohort, validation,

#4136 Peptide receptor radionuclide treatment in an outpatient setting – A single center experience

Introduction: Peptide receptor radionuclide therapy (PRRT) is an important treatment option for somatostatin receptor expressing non-resectable neuroendocrine tumors. Traditionally, this therapy has been provided as inpatient care. PRRT has been offered by Oslo University Hospital from November 2019, and organized mainly as outpatient care.

Conference:

Presenting Author:

Authors: Sponheim J, Dahle V, Skrede Mordal K, Solberg H, Åvitsland T,

Keywords: PRRT, outpatient care,

#3433 Role of [18 F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasia (NET) is a heterogeneous disease. While 68-Ga PET is considered the gold standard in GEP-NETs, the role of [18F]FDG PET/CT is not well established, particularly in well-differentiated G1 NETs.

Conference:

Presenting Author: Magi L

Authors: Magi L, Prosperi D, Lamberti G, Marasco M, Ambrosini V,

Keywords: Neuroendocrine tumor, disease aggressiveness, prognosis, management, PET,

#3416 MEN1 gene sequence variant C.[527 G> A] P.[ARG 176 GLN]: Is it pathogenic?

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare syndrome with a severe impact on quality of life of patients and their relatives and early diagnosis is mandatory. Many single-nucleotide polymorphisms of the MEN1 gene are reported, but only few are pathogenic.

Conference:

Presenting Author:

Authors: Zanata I, Crociara A, Ambrosio M, Bondanelli M, Aliberti L,

Keywords: MEN1, C.[527 G> A] P.[ARG 176 GLN], sequence variant,

#3268 Management and treatment of neuroendocrine tumors during the global COVID-19 pandemic - Experience of medical oncology department of hospital 1st November

Introduction: The current recommendations for management of neuroendocrine tumor diseases are still evolving, due to the limited experience on this issue. As the new coronavirus can be transmitted through breath droplets, by contact, there is no consensus of how this fact may affect the investigation and treatment of neuroendocrine tumor diseases.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Bengueddach A, Kaid M, Kehili H, Tidjene A, Bereksi Reguig F,

Keywords: neuroendocrine, covid-19, treatment,